Introduction {#S5}
============

Postoperative ileus (POI), a multi-factorial disorder, is commonly the result of gastrointestinal (GI) surgery[1](#C1). Surgical manipulation of the bowel leads to POI[1](#C1),[2](#C2). It has been theorized that endogenous stimulation of opioid receptors can contribute to this neurally mediated reflex[3--5](#C3 C4 C5). POI affects the entire GI tract[1](#C1),[6](#C6) and is associated with prolonged hospital stays at an estimated cost of more than \$1 billion annually[7](#C7).

Most patients who undergo major bowel surgery have moderate-to-severe pain requiring opioid analgesics. Opioids exacerbate and prolong POI by binding to µ-opioid receptors in the gut, resulting in decreased propulsive peristaltic waves and delayed intestinal transit[1](#C1),[2](#C2),[6](#C6),[8](#C8),[9](#C9). Conventional treatments, including nasogastric suction, prokinetic agents, early enteral feeding, and the use of minimally invasive surgical techniques, have not been proven effective in preventing or alleviating POI[1](#C1). A pharmacologic agent that selectively antagonizes the peripheral binding of opioids in the intestine while preserving central analgesia may be a useful treatment for POI. Peripheral µ-opioid receptor antagonists show promise in meeting these needs.

Naloxone has been shown to effectively reverse opioid-induced constipation[10--12](#C10 C11 C12). However, because it crosses the blood--brain barrier, it also reverses the analgesic effect of opioid treatments and produces withdrawal symptoms[2](#C2),[13](#C13). Methylnaltrexone, a peripheral µ-opioid receptor antagonist, is a quaternary derivative of naltrexone ([Figure 1](#F0001)). Methylnaltrexone has restricted access to the blood--brain barrier as a result of this modified structure[9](#C9),[14--16](#C14 C15 C16) and, thus, preserves central analgesia while reducing GI effects[1](#C1),[9](#C9),[13](#C13). Subcutaneous methylnaltrexone is approved by the US Food and Drug Administration for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has been insufficient[17](#C17). Studies have demonstrated rapid laxation compared with placebo in patients with advanced illness and opioid-induced constipation[18](#C18).

![Chemical structures of morphine, the non-selective opioid antagonist naltrexone, and the selective opioid antagonist methylnaltrexone.](ijda-2-127.01){#F0001}

The present study was conducted to assess the safety and activity of intravenous (IV) methylnaltrexone used to shorten the duration of POI in patients who underwent open segmental colectomy.

Patients and methods {#S6}
====================

This multi-center randomized, placebo-controlled phase 2 study was conducted in hospitals from July 2003 to December 2004. The protocol was approved by the ethics or institutional review board at each site and the study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki. Written informed consent was obtained from each patient prior to participation. Adult patients (18 years of age or older) with an American Society of Anesthesiologists physical status of I, II, or III who had undergone segmental colectomy---including partial colectomy, sigmoidectomy, cecectomy, or anterior proctosigmoidectomy---via laparotomy with general anesthesia were enrolled. Women of childbearing age were required to have negative pregnancy tests and use reliable birth control. All patients had received a standardized general anesthetic and used patient-controlled IV opioids for postoperative pain relief.

Patients were excluded if they had undergone surgery for complications related to inflammatory bowel disease, had recent abdominal radiation therapy, had surgery-related ostomies, or had received spinal or epidural anesthesia or analgesia. Other exclusion criteria included sensitivity to study medication or opioids, treatment with an investigational drug within the previous 30 d, prior treatment with vinca alkaloids, or significant medical history that may complicate the postoperative course, including a prolonged QTc interval.

This was a hypothesis-generating study; therefore, there was no pre-defined primary efficacy endpoint. All efficacy variables were considered exploratory. Efficacy was evaluated 4-times daily, regardless of study drug administration, using the gastrointestinal assessments listed in [Table 1](#TB1){ref-type="table"}. In addition, time to first micturation after removal of the urinary catheter, time to administration of rescue antiemetics, and the amount of morphine-equivalent[19--26](#C19 C20 C21 C22 C23 C24 C25 C26) opioid medications administered were evaluated.

###### 

Gastrointestinal efficacy measures.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  • Time to tolerance of solid foods: no nausea or vomiting within 60 min of a second consecutive solid meal. The time to the endpoint was recorded as the time of the conclusion of the first solid meal. Meals had to be consumed within 2 h and the patient was required to eat \>50% of the solid food
  • Time to first bowel movement
  • Time to discharge eligibility: tolerating solid foods, having had at least one bowel movement, normal body temperature, and no major complications (patients may have been discharged before reaching discharge eligibility)
  • Time to solids-in, solids-out: toleration of solids and first bowel movement
  • Time to actual discharge
  • Time to first passage of flatus
  • Time to gastrointestinal recovery: toleration of solids and first bowel movement or flatus
  • Time to first tolerance liquid: 30 mL liquid by mouth with no nausea or vomiting within first 60 min of challenge
  • Time to first tolerance of full liquids: \>500 mL at the meal following tolerance of first 30 mL liquid with no nausea or vomiting within first hour of conclusion of full liquids
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study design {#S0006-S2001}
------------

Patients were randomized within 24 h prior to surgery to receive either IV methylnaltrexone (0.30 mg/kg in 50 mL of saline) or matching saline placebo allocated in a 1:1 ratio according to a randomization schedule prepared by Progenics Pharmaceuticals, Inc. that was provided to the investigational pharmacist at each study site. As each patient was enrolled in the study, the pharmacist opened the next sealed, sequentially numbered envelope containing the name of the study medication assigned to that patient. Only the pharmacist was unblinded at each site; the patients and investigators remained blinded during the study. The dose of 0.3 mg/kg methylnaltrexone was selected based on previous studies[15](#C15),[16](#C16). The first dose of study drug was administered within 90 min after the end of the surgical procedure. Study drug was administered intravenously over 20 min every 6 h until the patient could tolerate solid foods for 24 h, until the patient was discharged from the hospital, or until the patient received treatment for a maximum of 7 d.

Blood pressure and pulse were monitored prior to, at the end, and at 20, 60, 120, and 180 min after the first and second study drug infusions. For subsequent doses, they were monitored prior to and 20 min after dosing. Prior to and 60 min after the first study drug administration, then 4-times daily, patients were not only asked to assess their nausea, abdominal cramping, pain, and itching levels based on a verbal numeric scale (0--10 scale) but to also report on whether or not they had vomited. A 12-lead resting electrocardiogram (ECG) reading, physical examination findings and laboratory assessments (complete blood count and comprehensive metabolic panels) were obtained at the screening visit and at the end of treatment. Review of all concomitant medications and adverse event (AE) evaluations were performed at the beginning of and throughout the study. Patients were also monitored for any adverse effects at the follow-up 30 d after the last dose of study drug.

Statistical analysis {#S0006-S2002}
--------------------

Efficacy analyses used the intent-to-treat (ITT) population. The ITT population included all randomized patients who received at least one dose of study drug. Patients who discontinued treatment prematurely continued to be followed for efficacy through the end of the study. The primary objective was to assess the activity of methylnaltrexone on the duration of POI. A sample size of 30 patients per group was estimated to have ∼80% power to detect a minimum of 30 percentage points difference in the proportion of responders for a given endpoint at the 5% level of significance. Continuous endpoints were summarized by treatment group/study day and during the entire postoperative period and analyzed using a Wilcoxon signed-rank test. Categorical variables were tested using Pearson's *χ*^2^ test for contingency tables. The distributions of efficacy event times were estimated using product limit (Kaplan-Meier) methods and compared between treatment groups by the 2-sided log-rank test. All statistical comparisons were performed at the 0.05 level of statistical significance without multiplicity adjustments.

All patients who received at least one dose of study drug were included in the analysis of the safety data. The number/percentage of patients experiencing one or more AEs or with any specific AE occurring in more than 5% of patients was tabulated.

Results {#S7}
=======

Of the 94 patients screened, 65 patients (33 in the methylnaltrexone group and 32 in the placebo group) were randomized and treated after surgery ([Figure 2](#F0002)). Of these, 52 patients (29 in the methylnaltrexone group and 23 in the placebo group) completed treatment. Of the four patients in the methylnaltrexone group who discontinued treatment, one discontinued because of nausea, one was determined to be ineligible, one was withdrawn because of an investigator's decision, and one patient withdrew on request. In the placebo group, nine patients discontinued, three because of nausea, one because of urticaria, one owing to an abdominal hematoma, one because of pneumonia, and three who withdrew consent.

![Patient disposition. \*One ineligible patient was randomized to placebo but drug was not dispensed.](ijda-2-127.02){#F0002}

The demographic and baseline characteristics of the patients were similar between the treatment groups ([Table 2](#TB2){ref-type="table"}). The most common surgery type overall was sigmoid resection, and analyses of this patient sub-group showed similar trends of efficacy results to that of the entire population.

###### 

Baseline patient demographics\*.

  Characteristic             Methylnaltrexone (*n* = 33)   Placebo (*n* = 32)   Total (*n* = 65)
  -------------------------- ----------------------------- -------------------- ------------------
  Gender, *n* (%)                                                               
   Male                      12 (36)                       14 (44)              26 (40)
   Female                    21 (64)                       18 (56)              39 (60)
  Race, *n* (%)                                                                 
   White                     27 (82)                       26 (81)              53 (82)
   Black                     6 (18)                        6 (19)               12 (18)
  Mean age, years (SD)       58.7 (13.8)                   54.8 (11.1)          56.8 (12.6)
  Mean weight, kg (SD)       76.9 (14.0)                   85.1 (19.5)          80.9 (17.3)
  Type of surgery, *n* (%)                                                      
   Sigmoid resection         17 (51.5)                     11 (34.4)            28 (43.1)
   Right hemicolectomy       7 (21.2)                      13 (40.6)            20 (30.8)
   Left hemicolectomy        2 (6.1)                       4 (12.5)             6 (9.2)
   Low anterior resection    5 (15.2)                      0                    5 (7.7)
   Colostomy takedown        0                             3 (9.4)              3 (4.6)
   Transverse colectomy      1 (3.0)                       1 (3.1)              2 (3.1)
   Total colectomy           1 (3.0)                       0                    1 (1.5)

\*Intent-to-treat population.

Efficacy {#S0007-S2001}
--------

Overall, patients receiving methylnaltrexone had a more favorable response for most efficacy measures compared with patients receiving placebo ([Table 3](#TB3){ref-type="table"}). The mean time to the first bowel movement was accelerated by 20 h in patients receiving methylnaltrexone (mean time 98.0 ± 5.7 h) compared with placebo (mean time 118.1 ± 10.3 h; *p* = 0.038 log-rank test), and time to discharge eligibility was accelerated by 33 h (mean times 116.1 ± 6.9 h for methylnaltrexone vs 148.7 ± 17.2 h for placebo; *p* = 0.049 log-rank test). Mean times to other measures of efficacy, including first tolerance of full liquids and first tolerance of solids, were accelerated among patients receiving methylnaltrexone compared with placebo but did not reach statistical significance. Only time to first tolerance of liquids was similar between the two treatment groups.

###### 

Mean time to gastrointestinal measures of efficacy\*.

  Efficacy variables                         Methylnaltrexone hours ± SD   Placebo hours ± SD   Difference hours   *p-*value^a^
  ------------------------------------------ ----------------------------- -------------------- ------------------ --------------
  First tolerance of solids                  97.4 ± 11.6                   123.9 ± 17.1         26.5               0.205
  First bowel movement                       98.0 ± 5.7                    118.1 ± 10.3         20.1               0.038
  Discharge eligibility                      116.1 ± 6.9                   148.7 ± 17.2         32.6               0.049
  Solids-in, solids-out                      124.1 ± 8.6                   151.2 ± 15.6         27.2               0.124
  Actual discharge                           138.3 ± 6.7                   164.5 ± 16.1         26.2               0.159
  First passage of flatus                    88.4 ± 6.5                    97.8 ± 10.0          9.4                0.327
  GI recovery^b^                             114.8 ± 9.4                   136.8 ± 15.9         22.0               0.263
  First tolerance of liquids (30 mL)         55.3 ± 7.6                    54.7 ± 9.2           −0.6               0.925
  First tolerance of full liquids (500 mL)   68.1 ± 9.0                    97.3 ± 18.7          29.2               0.119

\*Intent-to-treat population.

^a^Log-rank *χ*^2^.

^b^Gastrointestinal recovery defined as toleration of solids and first bowel movement or flatus.

The mean time to first administration of rescue antiemetics was longer for patients in the methylnaltrexone group (75.7 ± 12.8 h) than for those in the placebo group (31.3 ± 5.3 h), although the difference was not statistically significant (*p* = 0.411 log-rank test). At 60 min after the first administration of study drug, 6% of patients in the methylnaltrexone group and 12% of those in the placebo group reported vomiting.

Opioid use was similar between the two treatment groups immediately after surgery and on postoperative days (PODs) 2 and 3 ([Table 4](#TB4){ref-type="table"}). Opioid use steadily decreased from POD 1--4. Beyond POD 4, the levels of opioid use continued to decrease for the methylnaltrexone group for the rest of the study (up to day 8), but varied for the placebo group.

###### 

Daily opioid\* dose (mg) by treatment group.

      Methylnaltrexone   Placebo                  
  --- ------------------ ------------------- ---- -------------------
  1   32                 33.4 (8.0--271.9)   32   49.6 (6.7--295.2)
  2   31                 29.5 (2.2--538.0)   32   39.5 (6.7--309.8)
  3   31                 29.3 (2.2--318.0)   30   31.1 (0--309.8)
  4   27                 11.5 (0--70.0)      27   23.3 (0--383.2)
  5   18                 9.9 (0--70.0)       16   0.8 (0--46.7)
  6   12                 8.8 (0--70.0)       10   3.7 (0--45.8)
  7   10                 0 (0--70.5)         7    23.3 (0--73.7)
  8   8                  0 (0--28.9)         4    4.7 (0--62.6)

\*Intravenous morphine equivalent[19--26](#C19 C20 C21 C22 C23 C24 C25 C26).

Patient assessments of pain using the verbal numeric scale generally decreased from POD 1--7 in both treatment groups. The scores were similar between the two treatment groups at each time point. On Day 1 before dosing, pain scores were 6.33 and 6.67 in the methylnaltrexone and placebo groups, respectively. These scores decreased to 5.55 and 5.35 60 min post-dose, to 3.44 and 3.46 at the end of POD 1, and continued to decrease in a similar manner in both treatment groups through POD 7. There was little evidence of nausea, cramping, or itching.

Safety {#S0007-S2002}
------

Methylnaltrexone was generally well tolerated (see [Table 5](#TB5){ref-type="table"} for a summary of AEs occurring in at least 10% of patients in either treatment group). Gastrointestinal AEs were reported more frequently in the placebo group compared with the methylnaltrexone group, including nausea (63% vs 30%, respectively), vomiting (25% vs 12%, respectively), and abdominal pain (13% vs 0%, respectively).

###### 

Adverse events reported in ≥10% of patients in either treatment group.

  Adverse event            Methylnaltrexone (*n* = 33), *n* (%)   Placebo (*n* = 32), *n* (%)
  ------------------------ -------------------------------------- -----------------------------
  Pyrexia                  11 (33)                                12 (38)
  Nausea                   10 (30)                                20 (63)
  Hypotension              6 (18)                                 3 (9)
  Pruritus                 6 (18)                                 7 (22)
  Hypomagnesemia           5 (15)                                 5 (16)
  Urine output decreased   5 (15)                                 5 (16)
  Hypocalcemia             4 (12)                                 3 (9)
  Hypophosphatemia         4 (12)                                 4 (13)
  Vomiting                 4 (12)                                 8 (25)
  Hypokalemia              3 (9)                                  5 (16)
  Hypoxia                  3 (9)                                  6 (19)
  Hypertension             2 (6)                                  5 (16)
  Postoperative ileus      2 (6)                                  5 (16)
  Dyspnea                  1 (3)                                  4 (13)
  Wound infection          1 (3)                                  4 (13)
  Abdominal pain           0 (0)                                  4 (13)
  Headache                 0 (0)                                  6 (19)

Symptoms associated with prolonged POI were reported as an AE by the investigators. The incidence of POI, reported as an AE, was reduced 2-fold in patients treated with methylnaltrexone compared with patients on placebo. POI, reported as an AE, occurred in five (16%) patients in the placebo group and in two (6%) patients in the methylnaltrexone group. Hypotension was the only AE notably more frequent in the methylnaltrexone group compared with the placebo group (18% vs 9%, respectively), and all occurrences were mild-to-moderate (grades 1 or 2 according to Common Toxicity Criteria, version 2.0) in severity and judged by the investigators as not related or unlikely to be related to study medication.

Adverse events possibly related to study drug occurred in three patients receiving methylnaltrexone (diarrhea, insomnia, and pruritus) and in two patients receiving placebo (nausea and hypotension). All were mild-to-moderate in severity. Serious AEs that occurred during the treatment and follow-up periods are reported in [Table 6](#TB6){ref-type="table"}. All of the serious AEs resolved and none were judged to be related to study drug. No deaths occurred in this study.

###### 

Serious adverse events.

  Study period   Treatment group    Adverse events^a^
  -------------- ------------------ -------------------------------------------------------------------------------------------------------
  Treatment      Placebo            Enterocutaneous fistula, wound dehiscence
                 Placebo            Pneumonia
  Follow-up      Placebo            Ureteric obstruction
                 Placebo            Enterocutaneous fistula, wound dehiscence
                 Methylnaltrexone   Supraventricular tachycardia, ruptured resection, anastomotic leak, postoperative ileus, hyperkalemia
                 Placebo            Pneumonia
                 Placebo            Abdominal pain^b^

^a^Individual patients with adverse event.

^b^Abdominal pain was reported as three adverse events in this patient.

The clinically significant laboratory findings that occurred during the study included low hemoglobin, hematocrit, and red blood cells in eight patients, three of whom were in the placebo group and five in the methylnaltrexone group. All clinically significant laboratory abnormalities were attributed to an underlying disease. For vital signs and ECGs, the changes from baseline within the treatment group and the differences between treatment groups were relatively small, consistent with postoperative recovery in these patients, and not indicative of any clinically relevant effect of the investigational drug.

Discussion {#S8}
==========

In this study, patients receiving methylnaltrexone had a more rapid recovery of bowel function than those receiving placebo.

Notably, the mean time to first bowel movement was accelerated by 20 h in patients treated with methylnaltrexone compared with those receiving placebo. Patients receiving methylnaltrexone also had shorter times to first tolerance of full liquids and solids compared with those receiving placebo, although the differences between groups did not reach statistical significance. The mean time to antiemetic use was longer for patients receiving methylnaltrexone compared with those receiving placebo, although this difference did not reach statistical significance. Many patients did not require antiemetics during the 7-day study period. The increased and earlier use of antiemetics among patients who received placebo is consistent with the increased incidence of GI AEs, such as nausea and vomiting, compared with patients who received methylnaltrexone. The use of individual endpoints of gastrointestinal function allow for a better characterization of the effect of methylnaltrexone on upper and lower bowel recovery. These results suggest that IV methylnaltrexone may improve postoperative recovery of both upper and lower GI functions.

Time to discharge eligibility was significantly shorter among patients receiving methylnaltrexone compared with placebo (*p* = 0.049 log-rank test). The difference between the treatment groups is clinically relevant and may have an added economic benefit of reducing post-surgical hospital stays. Time to discharge eligibility is a composite endpoint, defined as the ability to tolerate solid foods, passage of at least one bowel movement, normal body temperature, and the absence of major complications. Because actual discharge may be influenced by factors unrelated to POI or by factors unrelated to medical status, discharge eligibility is a more meaningful measure in this study.

Overall, methylnaltrexone was well tolerated. Patients receiving placebo were more likely to report GI AEs, as well as headache, hypoxia, hypertension, and dyspnea, compared with those receiving methylnaltrexone. Hypotension was the only AE reported notably more often among patients receiving methylnaltrexone compared with placebo. Pain, as assessed by patients using the verbal numeric scale, was similar and generally decreased over time in both treatment groups during the study. Opioid use was also similar between both treatment groups. The similarity in pain intensity rating and opioid use between the treatment groups supports the peripheral µ-opioid receptor action of methylnaltrexone and preservation of central µ-opioid receptor activity.

It is interesting to note that although nausea and vomiting were reported as AEs twice as often in the placebo group compared with methylnaltrexone, between-group differences were not evident on patient assessments recorded using the verbal numeric scale. The apparent inconsistency between the patient assessments and reported AEs may be explained by differences in how the data were captured. Whereas AEs were collected through spontaneous patient reports, direct questioning, laboratory assessments, and physical examination findings, the verbal numeric scale evaluated the level of nausea, vomiting, cramping, and itching specifically at the time of the assessment.

In this study, treatment with IV methylnaltrexone at a dose of 0.30 mg/kg administered every 6 h for up to 7 d in patients after segmental colectomy appeared to be well tolerated. The lower incidence of GI AEs in patients treated with methylnaltrexone compared with placebo is consistent with the activity of methylnaltrexone in shortening the time to recovery from POI.

Clear identification of the return of normal bowel function following GI surgery is a challenge. Typically, motility is believed to be restored within 24 h after surgery in the stomach and small bowel and within 48--72 h in the colon[27](#C27),[28](#C28). However, there is no standard definition of persistent ileus, the typical period for ileus to last, or endpoints to determine recovery of bowel function[7](#C7). Endpoints that are typically used, such as time to first tolerance of food or time to first flatus, are based on studies involving small numbers of patients. Further complicating the selection of endpoints for GI recovery is the recurrence of POI more than a day after it has resolved[7](#C7). The specific GI efficacy endpoints used in our study are intended to provide a broad characterization of complete GI recovery.

These current findings are consistent with another µ-opioid receptor antagonist, alvimopan, which is approved in the US for acceleration of the time to upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis[29](#C29). In clinical trials, alvimopan exhibited advantages in some GI recovery endpoints while failing to reach significance in others[30--32](#C30 C31 C32). In contrast, results of two phase 3 studies of IV methylnaltrexone, each with ∼500 patients undergoing open segmental colectomy, failed to show an improvement in time to first bowel movement and in other GI recovery endpoints[33](#C33). The reasons for these findings are unclear, although issues related to the dose, timing of the first dose, and choice of primary outcome measure have been discussed previously[33](#C33).

Conclusions {#S9}
===========

In this phase 2 study, IV methylnaltrexone significantly decreased the time to postoperative bowel recovery, as evidenced by a reduction in time to first bowel movement and discharge eligibility. Additional research is necessary to further assess the conditions under which methylnaltrexone may show benefit in patients with postoperative ileus.
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